Both miRNA-370 and miRNA-10a regulate angiogenesis [36,38,53], a VEGF-dependent biological process involved in the pathophysiology and therapy of HHT [54,55], by targeting, at least, the VEGF receptors (VEGFR) KDR (kinase insert domain receptor) [38,39] and FLT1 (fms-related tyrosine kinase 1) [45], respectively. This evidence concerns the gene FLT1 and hereditary hemorrhagic telangiectasia.